Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study

Jókai, Hajnalka; Szakonyi, József; Kontár, Orsolya; Marschalkó, Márta; Szalai, Klára; Kárpáti, Sarolta; Holló, Péter

doi:10.1016/j.jaad.2013.06.019

Cited by 74 publications

(70 citation statements)

References 48 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of our study support the notion of a potential protective effect of TNFi on cardiovascular risk in psoriatic disease . Several small studies showed beneficial effects of TNFi on subclinical indices of atherosclerosis, including intima‐media thickness, coronary flow reserve, and pulse wave velocity, in patients with psoriatic disease . However, to date, no study has investigated the impact of TNFi on atherosclerotic plaque, the end‐stage structural lesion of atherosclerosis and a strong independent predictor of clinical cardiovascular events.…”

Section: Discussionsupporting

confidence: 87%

Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease

Eder

Joshi

Dey

et al. 2018

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 87%

Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease

Eder

Joshi

Dey

et al. 2018

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…We observed increased FDG uptake in psoriasis patients’ blood vessels, which supports evolving epidemiological evidence that psoriasis raises cardiovascular risk, including major adverse cardiovascular events (myocardial infarction, stroke, cardiovascular death) [4]. This observed increase in vascular inflammation was most recently confirmed in a study demonstrating that systemic therapy for psoriasis may decrease vascular inflammation by FDG PET CT [5], and by ultrasonographic techniques such as carotid intimal medial thickness [6]. …”

Section: Dear Editorsupporting

confidence: 82%

Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique

Dave

Ahlman

Lockshin³

et al. 2014

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Pina et al . showed that adalimumab therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis, while Jokái et al . in a pilot study showed decrease of IMT after treatment with adalimumab, infliximab and etanercept.…”

Section: Introductionmentioning

confidence: 99%

Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study

Gkalpakiotis

Arenberger

Gkalpakioti

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-a, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: Creactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/b-glycoprotein I complex (oxLDL/b2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P < 0.05), oxLDL-b2GPI complex (P < 0.05), E-selectin (P < 0.001) and IL-22 (P < 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P < 0.001) and IL-22 (P < 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-a seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.

show abstract

Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study

Cited by 74 publications

References 48 publications

Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease

Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease

Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique

Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study

Contact Info

Product

Resources

About